Travere Therapeutics (NASDAQ:TVTX) CFO Christopher Cline Sells 50,508 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher Cline sold 50,508 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total value of $3,148,668.72. Following the transaction, the chief financial officer owned 87,508 shares in the company, valued at approximately $5,455,248.72. This trade represents a 36.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Performance

NASDAQ:TVTX opened at $64.74 on Friday. The stock has a fifty day moving average price of $61.63 and a 200-day moving average price of $48.50. The company has a market cap of $6.10 billion, a price-to-earnings ratio of -140.74 and a beta of 1.05. The company has a debt-to-equity ratio of 24.58, a quick ratio of 3.99 and a current ratio of 4.05. Travere Therapeutics, Inc. has a fifty-two week low of $22.06 and a fifty-two week high of $68.73.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.The company had revenue of $169.58 million for the quarter, compared to analyst estimates of $157.27 million. During the same period in the prior year, the firm posted $0.13 EPS. Travere Therapeutics’s quarterly revenue was up 48.2% on a year-over-year basis. As a group, equities analysts anticipate that Travere Therapeutics, Inc. will post -0.54 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on TVTX shares. TD Cowen raised their target price on shares of Travere Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. HC Wainwright increased their price target on shares of Travere Therapeutics from $57.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Guggenheim boosted their price objective on shares of Travere Therapeutics from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Evercore set a $78.00 target price on Travere Therapeutics in a research note on Monday, August 10th. Finally, Weiss Ratings downgraded Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $68.00.

Key Stories Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
• Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC increased its position in Travere Therapeutics by 53.4% during the 2nd quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after purchasing an additional 211 shares in the last quarter. Corient Private Wealth LP lifted its stake in Travere Therapeutics by 1.4% in the 2nd quarter. Corient Private Wealth LP now owns 48,125 shares of the company’s stock valued at $2,734,000 after purchasing an additional 648 shares during the last quarter. ProShare Advisors LLC boosted its position in Travere Therapeutics by 4.1% in the fourth quarter. ProShare Advisors LLC now owns 19,007 shares of the company’s stock valued at $726,000 after buying an additional 756 shares in the last quarter. Allworth Financial LP bought a new stake in shares of Travere Therapeutics during the second quarter worth $47,000. Finally, Swiss National Bank increased its holdings in shares of Travere Therapeutics by 0.6% during the first quarter. Swiss National Bank now owns 168,100 shares of the company’s stock worth $4,994,000 after buying an additional 1,000 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.